Privi Speciality Chemicals Limited has received a ‘no objection’ observation letter from the National Stock Exchange of India (NSE) regarding its proposed scheme of amalgamation. The move involves merging Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited into the parent company. This development marks a key procedural step in the company’s organizational restructuring plan, which was initially approved by the Board of Directors on December 19, 2025.
Advancing the Amalgamation Process
Following the formal approval of the proposed amalgamation scheme on December 19, 2025, Privi Speciality Chemicals Limited has reached a significant milestone. On May 05, 2026, the company received an official ‘no objection’ observation letter from the National Stock Exchange (NSE). This development signifies progress in the consolidation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited into the company’s existing corporate structure.
Next Steps and Regulatory Compliance
The company confirmed that while the NSE has cleared the path for the scheme, the firm is currently awaiting a similar observation letter from the BSE. This restructuring initiative, conducted under the provisions of the Companies Act, 2013, remains subject to further necessary regulatory and statutory approvals. The company continues to maintain transparency by hosting relevant updates on its investor relations portal for shareholders and stakeholders.
Source: BSE
